These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 39352419)

  • 1. Cost-effectiveness analysis of selpercatinib versus chemotherapy and pembrolizumab in the first-line treatment of rearranged during transfection fusion-positive non-small cell lung cancer in the United States.
    Yi H; Cao Y; Shi F; Wei X; Han S
    Int J Clin Pharm; 2024 Dec; 46(6):1427-1435. PubMed ID: 39352419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.
    She L; Hu H; Liao M; Xia X; Shi Y; Yao L; Ding D; Zhu Y; Zeng S; Shen L; Huang J; Carbone DP
    Lung Cancer; 2019 Dec; 138():88-94. PubMed ID: 31655368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China.
    Lang W; Ai Q; He Y; Pan Y; Jiang Q; Ouyang M; Sun T
    Int J Clin Pharm; 2024 Dec; 46(6):1536-1545. PubMed ID: 39276261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
    Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.
    Aziz MIA; Tan LE; Tan WHG; Toh CK; Loke LPY; Pearce F; Ng K
    J Med Econ; 2020 Sep; 23(9):952-960. PubMed ID: 32462958
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA.
    Zeng X; Wan X; Peng L; Peng Y; Ma F; Liu Q; Tan C
    BMJ Open; 2019 Dec; 9(12):e031019. PubMed ID: 31831534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC.
    Wan N; Zhang TT; Hua SH; Lu ZL; Ji B; Li LX; Lu LQ; Huang WJ; Jiang J; Li J
    Cancer Med; 2020 Mar; 9(5):1683-1693. PubMed ID: 31945265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of amivantamab plus chemotherapy for non-small cell lung cancer patients with epidermal growth factor receptor exon 20 insertions in the United States.
    Cao Y; Yi H; Shi F; Wei X; Han S
    Int J Clin Pharm; 2024 Dec; 46(6):1335-1344. PubMed ID: 38990458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50.
    Kuznik A; Smare C; Chen CI; Venkatachalam M; Keeping S; Atsou K; Xu Y; Wilson F; Guyot P; Chan K; Glowienka E; Konidaris G
    Value Health; 2022 Feb; 25(2):203-214. PubMed ID: 35094793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CNS Protective Effect of Selpercatinib in First-Line
    Pérol M; Solomon BJ; Goto K; Park K; Nadal E; Bria E; Martin C; Bar J; Williams JN; Puri T; Li J; Uh MK; Lin BK; Zhou C
    J Clin Oncol; 2024 Jul; 42(21):2500-2505. PubMed ID: 38828957
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated
    Solomon BJ; Zhou CC; Drilon A; Park K; Wolf J; Elamin Y; Davis HM; Soldatenkova V; Sashegyi A; Lin AB; Lin BK; F Loong HH; Novello S; Arriola E; Pérol M; Goto K; Santini FC
    Future Oncol; 2021 Mar; 17(7):763-773. PubMed ID: 33150799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atezolizumab monotherapy as first-line treatment for non-small cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a cost-effectiveness analysis in the USA.
    Li B; Rong D; Lin H
    BMJ Open; 2024 Nov; 14(11):e083716. PubMed ID: 39532375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
    Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
    J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
    [No Abstract]   [Full Text] [Related]  

  • 14. Sintilimab plus chemotherapy with or without bevacizumab biosimilar IBI305 in EGFR-mutated non-squamous NSCLC patients who progressed on EGFR TKI therapy: A China-based cost-effectiveness analysis.
    Peng J; Xu H; Liu Q
    PLoS One; 2024; 19(10):e0312133. PubMed ID: 39423210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden.
    Criss SD; Palazzo L; Watson TR; Paquette AM; Sigel K; Wisnivesky J; Kong CY
    PLoS One; 2020; 15(1):e0228288. PubMed ID: 31995619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
    Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
    J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels.
    Weng X; Luo S; Lin S; Zhong L; Li M; Xin R; Huang P; Xu X
    Oncol Res; 2020 Mar; 28(2):117-125. PubMed ID: 31610828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US.
    Insinga RP; Vanness DJ; Feliciano JL; Vandormael K; Traore S; Burke T
    J Med Econ; 2018 Dec; 21(12):1191-1205. PubMed ID: 30188231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
    Liu Q; Tan C; Yi L; Wan X; Peng L; Li J; Luo X; Zeng X
    PLoS One; 2021; 16(11):e0258605. PubMed ID: 34780478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China.
    Liao W; Huang J; Hutton D; Li Q
    J Med Econ; 2019 Apr; 22(4):344-349. PubMed ID: 30646794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.